16687-59-5

Basic information

• Product Name: 1-ETHYL-1,2,3,4-TETRAZOLE
• Synonyms: 1-ETHYL-1,2,3,4-TETRAZOLE;5-ethyl-1H-tetrazole(SALTDATA: FREE);5-ethyl-2H-tetrazole
• CAS NO: 16687-59-5
• Molecular Formula: C₃H₆N₄
• Molecular Weight: 98.11
• Mol File: 16687-59-5.mol

Chemical Properties

• Melting Point: 98-99 °C
• Boiling Point: 232.5°Cat760mmHg
• Flash Point: 110.2°C
• Appearance: /
• Density: 1.222g/cm³
• Vapor Pressure: 0.0587mmHg at 25°C
• Refractive Index: 1.522
• PKA: 5.07±0.10(Predicted)
• CAS DataBase Reference: 1-ETHYL-1,2,3,4-TETRAZOLE(CAS DataBase Reference)
• NIST Chemistry Reference: 1-ETHYL-1,2,3,4-TETRAZOLE(16687-59-5)
• EPA Substance Registry System: 1-ETHYL-1,2,3,4-TETRAZOLE(16687-59-5)

Safety Data

• Hazardous Substances Data: 16687-59-5(Hazardous Substances Data)

Usage

Uses

Used in Organic Synthesis:
1-Ethyl-1,2,3,4-tetrazole serves as a reagent and a building block in the synthesis of various organic compounds. Its unique structure and properties make it a valuable component in the creation of complex organic molecules.
Used in Pharmaceutical Research:
In the pharmaceutical industry, 1-Ethyl-1,2,3,4-tetrazole is used as a reagent and a building block for the development of new pharmaceutical compounds. Its presence in the molecular structure can influence the pharmacological properties of the resulting drugs, contributing to their efficacy and safety.
Used in Metalworking Fluids:
1-Ethyl-1,2,3,4-tetrazole functions as a complexing agent and a corrosion inhibitor in metalworking fluids. It helps to prevent the corrosion of metal surfaces during manufacturing processes, thereby extending the life of machinery and improving the quality of the final product.
Used in the Production of Surfactants and Dyes:
This chemical compound is also utilized in the production of surfactants and dyes, where it contributes to the formation of color and stability of these products.
Used in Medical Research:
1-Ethyl-1,2,3,4-tetrazole has been studied for its potential therapeutic applications in treating various medical conditions, such as hypertension, cancer, and inflammation. Its unique chemical properties may offer new avenues for the development of novel treatments and therapies.

InChI:InChI=1/C3H6N4/c1-2-3-4-6-7-5-3/h2H2,1H3,(H,4,5,6,7)

Upstream product

• 107-12-0 propiononitrile 
• 18755-47-0 5-vinyltetrazole 
• 123-38-6 propionaldehyde 

Downstream Products

• 114065-11-1 N-[1-(5-Ethyl-tetrazol-2-yl)-prop-(Z)-ylidene]-N'-(4-nitro-phenyl)-hydrazine 
• 114064-58-3 N-[1-(5-Ethyl-tetrazol-1-yl)-prop-(Z)-ylidene]-N'-(4-nitro-phenyl)-hydrazine 
• 90329-50-3 5-ethyl-1-methyl-1H-tetrazole 
• 148279-19-0 5-ethyl-2-methyl-2H-tetrazole 
• 1001416-70-1 ((R)-1-{6-(2,2-diphenyl-ethylamino)-9-[(1R,4S)-4-(5-ethyl-tetrazol-2-yl)-cyclopent-2-enyl]-9H-purin-2-yl}-pyrrolidin-3-yl)-carbamic acid tert-butyl ester 

Relevant articles and documents

Catalytic conversion of 2,4,5-trisubstituted imidazole and 5-substituted 1H-tetrazole derivatives using a new series of half-sandwich (η6-p-cymene)Ruthenium(II) complexes with thiophene-2-carboxylic acid hydrazone ligands

A new series of half-sandwich (η6-p-cymene) ruthenium(II) complexes with thiophene-2-carboxylic acid hydrazide derivatives [Ru(η6-p-cymene)(Cl)(L)] [L = N'-(naphthalen-1-ylmethylene)thiophene-2-carbohydrazide (L1), N'-(anthracen-9-ylmethylene)thiophene-2-carbohydrazide (L2) and N'-(pyren-1-ylmethylene)thiophene-2-carbohydrazide (L3)] were synthesized. The ligand precursors and their Ru(II) complexes (1–3) were structurally characterized by spectral (IR, UV–Vis, NMR and mass spectrometry) and elemental analysis. The molecular structures of the ruthenium(II) complexes 1–3 were determined by single-crystal X-ray diffraction. All complexes were used as catalysts for the one-pot three-component syntheses of 2,4,5-trisubstitued imidazole and 5-substituted 1H-tetrazole derivatives. The catalytic studies optimized parameters as solvent, temperature and catalyst. The catalysts revealed very active for a broad range of aromatic aldehydes presenting either electron attractor or electron donor substituents and, although less active, moderate to high activities were observed for alkyl aldehydes.

Batch Versus Flow Lithiation–Substitution of 1,3,4-Oxadiazoles: Exploitation of Unstable Intermediates Using Flow Chemistry

1,3,4-Oxadiazoles are a common motif in pharmaceutical chemistry, but few convenient methods for their modification exist. A fast, convenient, high yielding and general α-substitution of 1,3,4-oxadiazoles has been developed using a metalation-electrophilic trapping protocol both in batch and under continuous flow conditions in contradiction to previous reports which suggest that α-metalation of this ring system results in ring fragmentation. In batch, lithiation is accomplished at an industrially convenient temperature, ?30 °C, with subsequent trapping giving isolated yields of up to 91 %. Under continuous flow conditions, metalation is carried out at room temperature, and subsequent in flow electrophilic trapping gave up to quantitative isolated yields. Notably, lithiation in batch at room temperature results only in ring fragmentation and we propose that the superior mixing in flow allows interception and exploitation of an unstable intermediate before decomposition can occur.

A zinc Lewis acid surface active agent for the preparation of 5' - substituted tetrazole compounds

The invention belongs to the field of organic synthetic technology, and specifically relates to a zinc Lewis acid surfactant as catalysts for preparing the 5' - substituted compound four azole class method. The method comprises the following steps: 1) to zinc Lewis acid surfactant Zn (OSO2 Cn H2 N + 1 )2 As the catalyst, R cyanide and sodium azide in water reaction to obtain the 5' - R base four nitrogen zuo compound of zinc salt and by-product NaOSO2 Cn H2 N + 1 ; 2) In the step 1) of the obtained 5 '- R base four nitrogen zuo compound of zinc salt in the acidification is carried out under acidic conditions, to obtain the 5' - R base four nitrogen zuo compounds and by-product zinc bromide; 3) by-product NaOSO2 Cn H2 N + 1 And by-product zinc bromide in the substitution reaction under acidic conditions, to obtain zinc Lewis acid surfactant Zn (OSO2 Cn H2 N + 1 )2 . Method can be used in "one-pot" strategy, the starting material by continuous cyclization reaction, the acidification reaction directly preparation containing the tetrazole compound of the structural unit; the method used in the zinc Lewis acid surfactant can be recovered after the reaction.

An improved protocol for the preparation of 5-substituted tetrazoles from organic thiocyanates and nitriles

Organic thiocyanates and nitriles are converted efficiently into the corresponding 5-substituted 1H-tetrazoles by treatment with zinc(II) chloride and sodium azide in aliphatic alcohols. The presented procedure provides mild reaction conditions, short reaction times, and good to excellent yields for a wide range of substrates, including deactivated aliphatic nitriles and thermally unstable thiocyanates. Georg Thieme Verlag Stuttgart · New York.

Efficient transformation of inactive nitriles into 5-substituted 1 H-tetrazoles using microwave irradiation and their applications

Efficient transformations of inactive nitriles into 5-substituted 1H-tetrazoles in DMF in a microwave reactor are described. The present method is applied to the synthesis of tetrazolato-bridged dinuclear platinum(II) complex and tetrazole C1-ribonucleoside phosphoramidite. Georg Thieme Verlag Stuttgart, New York.

FUSED BICYCLIC COMPOUNDS AS INHIBITORS FOR PI3 KINASE

The invention relates to compounds of formula (I) for the regulation of phosphoinositides 3-kinases activity and related diseases.

BICYCLIC HETEROARYL COMPOUNDS AND THEIR USE AS KINASE INHIBITORS

Phosphatidylinositol (PI) 3-kinase inhibitor compounds, their pharmaceutically acceptable salts, and prodrugs thereof; compositions of the new compounds, either alone or in combination with at least one additional therapeutic agent, with a pharmaceutically acceptable carrier; and uses of the new compounds, either alone or in combination with at least one additional therapeutic agent, in the prophylaxis or treatment of proliferative diseases characterized by the abnormal activity of growth factors, protein serine/threonine kinases, and phospholipid kinases.

PURINE DERIVATIVES AS A2A RECEPTOR AGONISTS

A compound of formula (I) or stereoisomers or pharmaceutically acceptable salts thereof.and their preparation and use as A2A receptor agonists

PURINE DERIVATIVES ACTING AS A2A RECEPTOR AGONISTS

Compounds of formula (I) in free or salt form, wherein R1, R2 and R3 have the meanings as indicated in the specification, are useful for treating conditions mediated by activation of the adenosine A2A receptor, especially inflammatory or obstructive airways diseases. Pharmaceutical compositions that contain the compounds and a process for preparing the compounds are also described.